Serveur d'exploration autour de Joseph Jankovic - Curation (Ncbi)

Index « Keywords » - entrée « Neuroprotective Agents (therapeutic use) »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Neuroprotective Agents (pharmacology) < Neuroprotective Agents (therapeutic use) < Neuropsychological Tests  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 14.
Ident.Authors (with country if any)Title
000004 (1999) Joseph Jankovic [États-Unis]New and emerging therapies for Parkinson disease.
000027 (2001) W Le [États-Unis] ; Joseph Jankovic [États-Unis]Are dopamine receptor agonists neuroprotective in Parkinson's disease?
000046 (2002) Joseph Jankovic [États-Unis] ; C. HunterA double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease.
000053 (2003) J Nutt [États-Unis] ; K Burchiel ; C Comella ; Joseph Jankovic [États-Unis] ; A Lang ; E Laws ; A Lozano ; R Penn ; R Simpson ; M. Stacy ; G WootenRandomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.
000054 (????) Madhavi Thomas [États-Unis] ; Wei Le ; Joseph Jankovic [États-Unis]Minocycline and other tetracycline derivatives: a neuroprotective strategy in Parkinson's disease and Huntington's disease.
000062 (2003) Tianhong Pan [États-Unis] ; Joseph Jankovic [États-Unis] ; Weidong LePotential therapeutic properties of green tea polyphenols in Parkinson's disease.
000063 (2003) Nicole Simpkins [États-Unis] ; Joseph Jankovic [États-Unis]Neuroprotection in Parkinson disease.
000067 (2003) Ron Tintner [États-Unis] ; Joseph Jankovic [États-Unis]Dopamine agonists in Parkinson's disease.
000089 (2005) C Olanow [États-Unis] ; Joseph Jankovic [États-Unis]Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy.
000188 (2008) Tianhong Pan [États-Unis] ; Seiji Kondo ; Wen Zhu ; Wenjie Xie ; Joseph Jankovic [États-Unis] ; Weidong LeNeuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement.
000206 (2008) C Olanow [États-Unis] ; Robert. Hauser ; Joseph Jankovic [États-Unis] ; William Langston ; Anthony Lang ; Werner Poewe ; Eduardo Tolosa ; Fabrizio Stocchi ; Eldad Melamed ; Eli Eyal ; Olivier RascolA randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
000275 (2010) Rodger Elble ; Oksana Suchowersky ; Stephanie Shaftman ; William Weiner ; Peng Huang ; Barbara TilleyImpact of belief in neuroprotection on therapeutic intervention in Parkinson disease
000447 (2014) Joseph Jankovic [États-Unis] ; Elijahu Berkovich [Israël] ; Eli Eyal [Israël] ; Eduardo Tolosa [Espagne]Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
000487 (2015) Benzi Kluger [États-Unis] ; Piera Triolo ; Wallace Jones ; Joseph Jankovic [États-Unis]The therapeutic potential of cannabinoids for movement disorders.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Ncbi/Curation
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i -k "Neuroprotective Agents (therapeutic use)" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/KwdEn.i  \
                -Sk "Neuroprotective Agents (therapeutic use)" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    JankovicV1
   |flux=    Ncbi
   |étape=   Curation
   |type=    indexItem
   |index=    KwdEn.i
   |clé=    Neuroprotective Agents (therapeutic use)
}}

Wicri

This area was generated with Dilib version V0.6.19.
Data generation: Wed Feb 10 22:03:07 2016. Site generation: Tue Feb 13 16:14:27 2024